| |
|
|
|
|
|
|
|
Alzheimer's disease
therapeutics - are we winning or losing?
Friday 16th
March 2012
Living Tomorrow Conference Centre, Brussels, Belgium |
|
Programme: |
|
|
|
Session 1 : |
|
|
|
|
10.00
|
Prof. John Hardy FRS, Institute of
Neurology, UK
Will new genetic findings in AD translate to
new therapies? |
|
10.40 |
Eric Karran, Institute of Neurology, UK
Testing the
amyloid cascade hypothesis in the clinic – a challenge to the current
paradigm. |
|
11.20 |
Prof Bart De Strooper, KULeuven, Belgium
Gamma secretase
as a target - is it over or just beginning? |
|
|
|
|
12.00 |
Lunch |
|
|
|
|
Session 2 : |
|
|
|
|
13.00 |
Harrie Gijssen,
Janssen Pharmaceuticals, Beerse, Belgium
Gamma secretase
modulators - current progress and challenges |
|
13.35 |
Andrew Stamford, PhD, Discovery
Chemistry, Merck Research Laboratories, Rahway, NJ
BACE inhibition – a tough target starts to yield |
|
14.10 |
Luca Santarelli, MD, Sr. VP, Head of
Neuroscience, Roche, Basel, Switzerland.
Gantenerumab and anti-Ab
antibodies – current
progress and future prospects. |
|
|
|
|
14.45 |
Coffee |
|
|
|
|
Session 3 : |
|
|
|
|
15.15 |
Marc Mercken, Janssen Pharmaceuticals, Beerse, Belgium.
Tau pathology–
opportunities for therapeutic intervention. |
|
15.50 |
Prof. Per I. Arvidsson, iMed Project
Director CNS & Pain, AstraZeneca
GSK3b
inhibitors as a potential target to ameliorate tau pathology. |
|
|
|
|
16.25 |
Close |
|
|
|
Back
to Menu
|
|
|
|
|
|
|
